Editorial Policy & Evidence Standards (E-E-A-T)

Published by the OncoGuides Clinical Governance Board

1. Commitment to Evidence-Based Onco-Nephrology

NephroOncoGuides produces content grounded strictly in peer-reviewed clinical nephrology, oncology pharmacokinetic trials, international consensus guidelines, and randomized trials. Our clinical synthesis reflects authoritative guidance from:

Kidney Disease: Improving Global Outcomes (KDIGO) — Acute Kidney Injury & Chronic Kidney Disease Guidelines
American Society of Clinical Oncology (ASCO) — Chemotherapy Nephrotoxicity Prevention & Management
European Society for Medical Oncology (ESMO) — Clinical Practice Guidelines on Renal Toxicities
International Myeloma Working Group (IMWG) — Consensus Criteria on Renal Impairment in Myeloma

2. Clinical Evidence Hierarchy

We classify all recommendations using standard international evidence hierarchies:

Level A: Supported by multiple randomized controlled trials, pharmacokinetic registration studies, or validated consensus equations (e.g. CKD-EPI 2021 race-free GFR, Calvert formula, Cairo-Bishop criteria).
Level B: Supported by prospective multicenter cohort registries (e.g. Glucarpidase Voraxaze rescue cohorts, Cortazar ICI-AIN cohort).
Level C: Supported by expert consensus, physiological transport principles, and institutional supportive hydration protocols.

3. Commercial Independence & Non-Bias

NephroOncoGuides maintains strict editorial independence. We do not accept pharmaceutical sponsorship, dialysis equipment manufacturer endorsements, or paid product placements.